Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Post 1/2.
I think this is important.
https://www.jtcvs.org/article/S0022-5223(08)00465-0/fulltext
Post 2/2.
“ RUA Structural Heart
The objectives for RUA Structural Heart for the period was to evaluate heart valve leaflet material and compare the performance of 100% polymeric valves with a novel composite developed by the Group. The computational modelling of the composite material at the design stage suggested that its mechanical properties would be ideal for heart valve leaflets and that there should not be a risk of delamination. The team within the Structural Heart business segment has very recently achieved the initial milestones set for the composite material. The Structural Heart team has achieved the initial milestones set for the composite material and we are delighted to report that after 200 million cycles the material shows no signs of delamination and cut edges remain unchanged as a result of flex fatigue. From a performance perspective, the composite material is very thin and flexible and little energy is required to open a valve and once opened does not restrict blood flow with a good EOA (Effective Orifice Area). Testing has also demonstrated that the properties of the composite restrict crack growth even in damaged leaflets.
100% polymeric valves rely in part on the leaflet design to reduce stress and operate within the performance window of the polymer meaning that polymer would not work in all designs. The composite material retains the blood contacting properties of Elast-Eon but is significantly stronger. This creates the opportunity for RUA Structural Heart to become a supplier of heart valve leaflets to other companies to incorporate in current designs.”
Sorry if teaching people to suck eggs, not my intention. The comment about energy efficiency of the valve caught my eye in the RNS. I think this is important. Both the energy to open the valve and that to maintain flow across the valve are low - if the research is correct. Less energy used by the valve means less disruptive / damaging force being experienced by the valve. Which should mean improved longevity of the valve.
I’m not a bioengineer, but do know quite a bit about blood flow in the human body - please don’t take that as arrogance.
Personally I think this it will be very Important if the major manufacturer confirms RUA’s findings.
And only one part of the corporate plans of the group.
Should we be worried there has not been one trade today ... an their isnt even a opening price or any trading ggoing on here ???
Why. Everyone apart from our bored 13 trade trader are happy waiting.
Its called investing.
13 trader sold 3k worth of stock for £100 probably he or she bought in at 13p.
Most of the trades on Friday, yesterday and today are my bed and isa . Hl have been putting them through the system since Friday they should be done by tomorrow
Atb
Why such small parcels, bud?
Not sure tbh
Its was like to 350k in 2 accounts thatI put through as bed and isa on Thursday. HLsaid the only cost would be he trading fee of £11 and the buy and sell price would be same. Got told it would take 4 working days
HL have completed both of my bed and isa now. The delayed trades showing from yesterday were the last lot
Gla
Well done N o N
I’m just kicking myself to buying a load over 13p when I should be buying now. I never learn!
I wish I was that lucky hh
My average price was around 13.5p . So I have taken a loss to move them into my isa account
Hopefully we will get some postive news soon and the sp can start moving up
Providing its a 1:1 transfer into the ISA, that’s a good thing. It means you’ve got more shares for your £20k limit?
Just could do with some news to get out of this range between 10-13p
From DEST post
One after the other biotech (AVCT, GDR, FAR and others) and others are going for placings.
Here, no placing for years ( the pain has already been endured) no warrants , 60m shares and an EV of around £3.5m - and you can still buy below last placing with updates soon.
Adds up to lower risk with high reward. Or at least, not a heart attack share, likely to be profitable H2 without the big one
Completely agree Jimzi, cash and two profitable strands to the business make it compelling risk reward with the two blue sky elements thrown in for free. Structural heart looks the most likely to bring a substantive re-rating but the contract manufacturing side also has the capacity (no pun intended!) to achieve that. Judging by a move up in level 2 by one MM it looks like the trades today are buys.
Correct NickE, the 10.68p for 50k was a purchase (mine). There’s still 50k available at 10.7 should anyone want it.
To me, this share is so ignored and unwanted, it’s a bit silly. Obviously, there is baggage left over from the fund raise last year that was announced a few days after that big spike when they gave the impression they were not going to raise. I was not impressed with the way that was done. It “wasn’t cricket” but investing is played with a hard ball and it doesn’t pay to hold grudges and get emotional.
Look at the situation now in the cold light of day. Is it a good bet now? The main risk to short term price is that they say the material under MTA is not being taken further by the major. But, as said by others, the basic CM and royalty businesses are still producing and they’ve definitely put the lid on R&D spending for now (eg, Vascular mothballed until a partner can be found).
Let’s hope for some positive noises.